medigraphic.com
ISSN 1727-897X (Electronic)

2022, Number 3

<< Back Next >>

Medisur 2022; 20 (3)

Hypokalemic thyrotoxic periodic paralysis. A case report

Rojas DCD, Rojas DAG

Language: Spanish
References: 13
Page: 568-571
PDF size: 114.15 Kb.


ABSTRACT

Hypokalemic thyrotoxic periodic paralysis is a rare entity, with a higher prevalence in males, and in the Asian population; characterized by muscle weakness, associated with hypokalaemia, and as a complication of hyperthyroidism, usually secondary to Graves' disease. Treatment is based on replacement of the potassium deficit, cardiovascular monitoring, and management of the underlying disease, with restoration of euthyroidism. A 38-years-old patient is presented, with several personal pathological antecedents, who came for medical assistance due to a 48-hour clinical picture of tetraparesis, with no other symptoms.


REFERENCES

  1. Vijayakumar A, Ashwath G, Thimmappa D. Thyrotoxic periodic paralysis: clinical challenges. J Thyroid Res. 2014;2014:649502.

  2. Patel H, Wilches LV, Guerrero J. Thyrotoxic periodic paralysis: Diversity in America. J Emerg Med. 2014;46(6):760-2.

  3. Pothiwala P, Levine SN. Analytic Review: Thyrotoxic Periodic Paralysis: A Review. Intensive Care Med. 2010;25(2):71-7.

  4. Li J, Yang XB, Zhao Y. Thyrotoxic periodic paralysis in the chinese population: Clinical features in 45 cases. Exp Clin Endocrinol Diabetes. 2010;118(1):22-6.

  5. Torres JF. Parálisis periódica hipopotasémica tirotóxica[Internet]. Ambato, Ecuador: Universidad Técnica de Ambato; 2021[citado 19/12/2021]. Disponible en: Disponible en: https://repositorio.uta.edu.ec/bitstream/123456789/33041/1/Torres%20Villa%2C%20Juan%20Francisco.pdf 5.

  6. Rhee EP, Scott JA, Dighe AS. A 37-year-old man with muscle pain, weakness, and weight loss. N Engl J Med. 2012;366(6):553-60.

  7. Arosemena M, Balda J, Sanchez J. Parálisis Periódica Hipopotasémica Tirotóxica, Una Emergencia Neuroendocrina: Artículo de Revisión. Rev Ecuat Neurol[Internet] 2020[citado 19/03/2021];29(3):[aprox. 10p]. Disponible en: http://revecuatneurol.com/wp-content/uploads/2020/12/2631-2581-rneuro-29-03-00092.pdf7.

  8. Shefner JM. Approach to the patient with muscle weakness[Internet]. Waltham, MA: UpToDate Inc.; 2021[citado 19/03/2021]. Disponible en: https://www.uptodate.com/contents/approach-to-the-patient-with-muscle-weakness/print?search=debilidad&source=search_result&selectedTitle...1/138.

  9. Mount D. Uptodate. Clinical manifestations and treatment of hypokalemia in adults[Internet]. Waltham, MA: UpToDate Inc; 2019[citado 25/10/2021]. Disponible en: Disponible en: https://www.uptodate.com/contents/clinical-manifestations-and-treatment-of-hypokalemia-in-adults 9.

  10. Sierra MA, Muñoz WR, Tolsa C, Lara AE, Medina R, Vega C. Parálisis periódica tirotóxica: revisión de la literatura y reporte de caso en un hospital universitario mexicano privado de alta especialidad. Rev Mex Neurocienc[Internet]. 2019[citado 25/10/2021];20(3):[aprox. 10p]. Disponible en: http://www.scielo.org.mx/scielo.php?pid=S1665-50442019000300149&script=sci_arttext10.

  11. Shiang JC, Cheng CJ, Tsai MK, Hung YJ, Hsu YJ, Yang SS, et al. Therapeutic analysis in Chinese patients with thyrotoxic periodic paralysis over 6 years. Eur J Endocrinol. 2009;161(6):911-6.

  12. Gutmann L, Conwit R. Hyperkalemic periodic paralysis[Internet]. Waltham, MA: UpToDate Inc; 2021[citado 25/10/2021]. https://www.uptodate.com/contents/hyperkalemic-periodic-paralysis 12.

  13. Chang RY, Lang BH, Chan AC, Wong KP. Evaluating the efficacy of primary treatment for graves' disease complicated by thyrotoxic periodic paralysis. Int J Endocrinol. 2014;2014:949068.




2020     |     www.medigraphic.com